16 Introduction: Key to pharmacovigilance is spontaneously reporting all Adverse Drug 17 Reactions (ADR) during post-market surveillance. This facilitates identification and 18 evaluation of previously unreported ADR's, acknowledging the trade-off between 19 benefits and potential harm of medications. Only 41% ADR's documented in Harare 20 city clinical records for January to December 2016 were reported to Medicines 21 Control Authority of Zimbabwe (MCAZ). We investigated reasons contributing to 22 underreporting of ADR's in Harare city. 23 24 Methods: A descriptive cross-sectional study and the updated Centers for Disease 25 Control (CDC) guided surveillance evaluation was conducted. Two hospitals were 26 purposively included. Seventeen health facilities and 52 health workers were 27 randomly selected. Interviewer-administered questionnaires, key informant interviews 28 and WHO pharmacovigilance checklists were used to collect data. Likert scales were 29 applied to draw inferences and Epi info 7 used to generate frequencies and 30 proportions. 31 32 Results: Of the 52 participants, 32 (61.5%) distinguished the ADR defining criteria. 33 Twenty-nine (55.8%) knew system's purpose whilst 28 (53.8%) knew the reporting 34 process. Knowledge scored average on the 5-point-Likert scale. Thirty-eight (73.1%) 35 participants identified ADR's following client complaints and nine (1.3%) enquired 36 clients' medication response. Forty-six (88.5%) cited non-feedback from MCAZ for 37 underreporting. Inadequate ADR identification skills were cited by 21 (40.4%) 38 participants. Reporting forms were available in five (26.3%) facilities and reports 39 were generated from hospitals only. Forty-two (90.6%) clinicians made therapeutic 40 decisions from ADR's. Averaged usefulness score was 4, on the 5-point-Likert scale. 41 All 642 generated signals were committed to Vigiflow by MCAZ, reflecting a case 42 detection rate of 4/ 100 000. Data quality was 0.75-1.0 (WHO) and all reports were 43 causally assessed. 44 45 Conclusion: The pharmacovigilance system was useful, simple, and acceptable 46 despite being unstable, not representative and not sensitive. It was threatened by 47 suboptimal health worker knowledge, weak detection strategies and referral policy 48 preventing ADR identification by person place and time. Revisiting local policy, 49 advocacy, communication and health worker orientation might improve 50 pharmacovigilance performance in Harare city. 51 52
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The bedrock of pharmacovigilance systems, that aim to improve medicinal products 83 safety, is prompt, spontaneous reporting of adverse drug reactions (ADRs) as a key 84 step to their mitigation as well as updating the drug information database (9) (10) (11) . It is, 85 therefore, a mandatory requirement for health care providers to timely report all 86 suspected and confirmed ADRs. This is particularly imperative in Zimbabwe, where 87 the treat all strategy is being implemented, since June 2016, and has resulted in the 88 number of people on HIV treatment rapidly increasing (12) .
89 A preliminary review of ADR data for ARV's from Harare City which was reported 90 through the MCAZ and through Opportunistic Infections (OI) records, captured 91 between 01 January and 31 December 2016 was conducted. A 41% discrepancy was 92 discovered in these two reporting systems, with more cases appearing in OI records 93 than what was reported to MCAZ (6) . This indicated poor reporting practices that 94 impede accurate quantification of the prevalence of ADR'S. Failure to detect and 95 report adverse drug reactions compromises patient safety and results in missed 96 opportunities to update drug safety profiles. It is within this background that we 97 evaluated the ADR surveillance system in Harare City in order to identify the reasons 98 for underreporting and recommend solutions. When an ADR case is suspected or confirmed, an in-house reference number is 101 assigned. 
Materials and Methods
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We conducted a descriptive cross-sectional study and surveillance system evaluation 118 using updated CDC guidelines for surveillance system evaluation as a mixed method.
119
Health Personnel involved in the ARV-ADR surveillance system were randomly 120 selected to participate in the evaluation. (14).
287
All the participants stated that it was their duty to fill the notification forms and were 288 willing to continue participating, hence the system was acceptable. However, the 
